Cleveland Biolabs Inc. (CBLI) Announces Publication of Studies on Effect of Entolimod (CBLB502) on Graft-Versus-Tumor Activity in Models of Allogeneic Bone Marrow Transplantation
11/6/2012 9:49:34 AM
BUFFALO, N.Y., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) announced today the online publication in the Journal of Immunology of a study demonstrating efficacy of Entolimod™ (previously known as CBLB502) in improving the graft-versus-tumor (GVT) activity of allogeneic bone marrow transplantation (allo-BMT) in a mouse model. The reported studies were conducted by scientists at Roswell Park Cancer Institute (RPCI) and Cleveland BioLabs.
comments powered by